- Home
- ABOS vs CNTB Comparison
ABOS vs CNTB Comparison
Compare ABOS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- CNTB
- Stock Information
- Founded
- ABOS 1996
- CNTB 2012
- Country
- ABOS United States
- CNTB United States
- Employees
- ABOS N/A
- CNTB N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- ABOS Health Care
- CNTB Health Care
- Exchange
- ABOS Nasdaq
- CNTB Nasdaq
- Market Cap
- ABOS 103.6M
- CNTB 90.3M
- IPO Year
- ABOS 2021
- CNTB 2021
- Fundamental
- Price
- ABOS $1.88
- CNTB $1.79
- Analyst Decision
- ABOS Strong Buy
- CNTB Strong Buy
- Analyst Count
- ABOS 3
- CNTB 2
- Target Price
- ABOS $8.00
- CNTB $7.50
- AVG Volume (30 Days)
- ABOS 410.3K
- CNTB 90.8K
- Earning Date
- ABOS 11-11-2025
- CNTB 11-13-2025
- Dividend Yield
- ABOS N/A
- CNTB N/A
- EPS Growth
- ABOS N/A
- CNTB N/A
- EPS
- ABOS N/A
- CNTB N/A
- Revenue
- ABOS N/A
- CNTB $1,965,000.00
- Revenue This Year
- ABOS N/A
- CNTB N/A
- Revenue Next Year
- ABOS N/A
- CNTB $453,067.90
- P/E Ratio
- ABOS N/A
- CNTB N/A
- Revenue Growth
- ABOS N/A
- CNTB N/A
- 52 Week Low
- ABOS $0.86
- CNTB $1.23
- 52 Week High
- ABOS $3.36
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- ABOS 67.95
- CNTB 55.28
- Support Level
- ABOS $1.67
- CNTB $1.36
- Resistance Level
- ABOS $1.86
- CNTB $1.58
- Average True Range (ATR)
- ABOS 0.16
- CNTB 0.15
- MACD
- ABOS 0.06
- CNTB 0.02
- Stochastic Oscillator
- ABOS 73.86
- CNTB 81.73
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.